Dear Editor,Non-small cell lung cancer(NSCLC)is the most common type of lung cancers.Since the majority of NSCLC patients are diagnosed at the advanced stage with a dramatic impact on the prognosis,chemotherapy is sti...Dear Editor,Non-small cell lung cancer(NSCLC)is the most common type of lung cancers.Since the majority of NSCLC patients are diagnosed at the advanced stage with a dramatic impact on the prognosis,chemotherapy is still the mainstay of treatment.Cisplatin(CDDP)remains one of the most widely used first-line drugs in the therapy of NSCLC,based on the clinical data that the poor outcomes of untreated NSCLC patients(5%overall survival at 1 year)have shown improvements in natural history of disease after CDDPbased chemotherapy(15%overall survival at 1 year).1 Nevertheless,Cisplatin has strong toxic side effects and many NSCLC patients treated with CDDP are easy to occur drug insensitivity,near-to-invariably leading to relapse and therapeutic failure.Therefore,finding novel target molecules which can regulate CDDP innate sensitivity is vital to improve clinical efficacy.For decades,a long-held consensus is that caspases-3-induced apoptosis is the major pattern for antitumor role of CDDP.The CDDP can promote cancer cell elimination via rewiring proproliferative signaling to pro-apoptotic pathway.However,apoptosis resistance readily occurs after CDDP treatment and it is of great significance to explore whether other types of programmed cell death can effectively heighten innate CDDP sensitivity.展开更多
基金funded by the National Natural Science Foundation of China(NSFC)project(No.81572994,81872491)Natural Science Foundation of Hunan project(No.2020JJ5857 to Y.L.and No.2020JJ5864 to Z.P.)Guangxi Science and Technology Research Base and Talent-specific Project(AD18126021)+1 种基金National Science and Technology Major Project for New Drug Innovation(2018ZX09733001-004-002)Key Laboratory of the Ministry of Education Project for Early Prevention and Treatment of Regional High-risk Tumors(GKE2018-03,GKE2019-09).
文摘Dear Editor,Non-small cell lung cancer(NSCLC)is the most common type of lung cancers.Since the majority of NSCLC patients are diagnosed at the advanced stage with a dramatic impact on the prognosis,chemotherapy is still the mainstay of treatment.Cisplatin(CDDP)remains one of the most widely used first-line drugs in the therapy of NSCLC,based on the clinical data that the poor outcomes of untreated NSCLC patients(5%overall survival at 1 year)have shown improvements in natural history of disease after CDDPbased chemotherapy(15%overall survival at 1 year).1 Nevertheless,Cisplatin has strong toxic side effects and many NSCLC patients treated with CDDP are easy to occur drug insensitivity,near-to-invariably leading to relapse and therapeutic failure.Therefore,finding novel target molecules which can regulate CDDP innate sensitivity is vital to improve clinical efficacy.For decades,a long-held consensus is that caspases-3-induced apoptosis is the major pattern for antitumor role of CDDP.The CDDP can promote cancer cell elimination via rewiring proproliferative signaling to pro-apoptotic pathway.However,apoptosis resistance readily occurs after CDDP treatment and it is of great significance to explore whether other types of programmed cell death can effectively heighten innate CDDP sensitivity.
